p21(WAF1/CIP1) mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells

Cancer Research

Volumn 58, Issue 22, 1998, Pages 5053-5056

  Welcker, Markus ^a   Lukas, Jiri ^a   Strauss, Michael ^a,b   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P21; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN;

ARTICLE; CARCINOGENESIS; GENE DELETION; HUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; CELL CULTURE; GENETICS; MELANOMA; METABOLISM; PHYSIOLOGY; POINT MUTATION; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; NEOPLASM PROTEINS; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED;

EID: 0032532951     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. El-Deiry, W., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
2. Waldman, T., Kinzler, K. W., and Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
3. Hengst, L., and Reed, S. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol., 227: 25-41, 1998.
4. El-Deiry, W. S. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol., 227: 121-137, 1998.
5. Ball, K. L., Lain, S., Fahraeus, R., Smythe, C., and Lane, D. P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol., 7: 71-80, 1996.
6. Luo, Y., Hurwitz, J., and Massagué, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (Lond.), 375: 159-161, 1995.
7. Nakanishi, M., Robetorye, R. S., Adami, G. R., Pereira, S. O., and Smith, J. R. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/ CIP1/WAF1. EMBO J., 14: 555-563, 1995.
8. Goubin, F., and Ducommun, B. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene, 10: 2281-2287, 1995.
9. Lin, J., Reichner, C., Wu, X., and Levine, A. J. Analysis of wild-type and mutant p21WAF-1 gene activities. Mol. Cell. Biol., 16: 1786-1793, 1996.
10. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L-H., Zhang, P., Dobrowoski, C. B., Connell-Crowley, L., Swindell, E., Fox, M. P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
11. Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., and Dutta, A. Cyclin-binding motifs are essential for the function of p21CIP1. Mol. Cell. Biol., 16: 4673-4682, 1996.
12. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
13. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
14. Shiohara, M., El-Deiry, W., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
15. Balbin, M., Hannon, G. J., Pendas, A. M., Ferrando, A. A., Vizoso, F., Fueyo, A., and Lopez, O. C. Functional analysis of a p21WAF1, CIP1, SDI1 mutant (Arg94 → Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J. Biol. Chem., 271: 15782-15786, 1996.
16. Bhatia, K., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J. G., and Magrath, I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res., 55: 1431-1435, 1995.
17. Gao, X., Chen, Y. Q., Wu, N., Grignon, D. J., Sakr, W., Porter, A. T., and Honn, K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene, 11: 1395-1398, 1995.
18. Vidal, M. J., Loganzo, F., de Oliveira, A. R., Hayward, N. K., and Albino, A. P. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res., 5: 243-250, 1995.
19. 1 checkpoint control. Cell, 82: 675-684, 1995.
20. 1 control in retinoblastoma gene-deficient cells, independently of cdk4 activity. Mol. Cell. Biol., 15: 2600-2611, 1995.